AI Custom Medium Development Service Featured in Various Media
The “AI Custom Media Development Service,” a joint service with Shimadzu Corporation and Shimadzu Diagnostics Corporation announced on February 19, 2026, was covered by various media outlets including Nikkei, Nikkei Biotech, and Mynavi News TECH+.
Media Coverage List
- Nikkei (Digital Edition)
- Nikkei (Kyoto Edition)
- Nikkei (Industry Section)
- Nikkei Biotech
- Mynavi News TECH+
- Yakuji Nippo
- Dempa Shimbun Digital
- Nikkei Biotech
- CTIWEB
- TBS NEWS DIG
- Otakuma Keizai Shimbun
- NIKKEI COMPASS
- Toremaga News
- RBBTODAY
- Jiji.com
- Niconico News
- Toyo Keizai Online
- Asahi Shimbun Digital Magazine &
- BtoB Platform Industry Channel
- Jiji Medical
- Infoseek News
- SEOTOOLS
- JBpress
- STRAIGHT PRESS
- PRESIDENT Online
- NewsPicks
- Nifty News
- @DIME
- Mapion News
- Sankei News
- Zaikei Shimbun
- Mainichi Shimbun Digital
- Nikkan Kogyo Shimbun Digital Edition
- Jordan News!
Related Articles
Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Epistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.